Zimin Y. Liu

16# Jiangsu Road
Qingdao, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 26, 2026

Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.

Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.

Journal: Frontiers in immunology

Published: November 25, 2025

EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer.

EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer.

Journal: MedComm

Published: November 03, 2025

Optimizing Postoperative Management in Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter Retrospective Study.

Optimizing Postoperative Management in Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter Retrospective Study.

Journal: Journal of gastric cancer

Published: September 21, 2025

The whole-course of supervised home-based multi-modal prehabilitation to improve clinical outcome in patients undergoing neoadjuvant chemotherapy prior to gastrectomy: a single-center randomized controlled trial.

The whole-course of supervised home-based multi-modal prehabilitation to improve clinical outcome in patients undergoing neoadjuvant chemotherapy prior to gastrectomy: a single-center randomized controlled trial.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: September 18, 2025

Endoscopic ultrasound features in predicting noncurative resection of endoscopic submucosal dissection in patients with rectal neuroendocrine neoplasms.

Endoscopic ultrasound features in predicting noncurative resection of endoscopic submucosal dissection in patients with rectal neuroendocrine neoplasms.

Journal: European journal of gastroenterology & hepatology

Published: July 31, 2025

Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.

Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: April 23, 2025

Correction: Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Correction: Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

Journal: BMC medicine

Published: February 12, 2025

Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis.

Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis.

Journal: Frontiers in immunology

Published: January 03, 2025

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.

Journal: Nature medicine

Published: December 10, 2024

Uric acid and related disorders in the risk of pancreatic diseases: A UK Biobank prospective study.

Uric acid and related disorders in the risk of pancreatic diseases: A UK Biobank prospective study.

Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Published: December 10, 2024

Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.

Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.

Journal: Frontiers in immunology

Published: November 24, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026